Dimerix

20TH BIOSHARES
BIOTECH SUMMIT
21 YEARS OF INNOVATION
2005-2026

Approaching Inflection Points

Bioshares Summit, Queenstown, NZ

6 August 2026

Developing new therapies to treat kidney diseases with unmet clinical needs

Authorised for lodgement by the Board of the Company

Forward looking statements

This presentation includes forward-looking statements that are subject to risks and uncertainties. Although we believe that the expectations reflected in the forward looking statements are reasonable at this time, Dimerix can give no assurance that these expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking statements.

Actual results could differ materially from those anticipated. Reasons may include risks associated with drug development and manufacture, risks inherent in the regulatory processes, delays in clinical trials, results of clinical trials, contractual risks, risks associated with patent protection, future capital needs or other general risks or factors, including but not limited to those factors outlined in the most recent Dimerix Limited Annual Report.

From single bets to sustainable growth

Question posed to Dimerix:

Diversifying for success:

1. **How is Dimerix reducing its risk through diversification, both geographically and through a product portfolio?**
2. **What are the key attributes and value drivers that make DMX-652 an attractive licensed-in asset?**
3. **If DMX-200 successfully makes it to market in all currently licensed territories, what is the total in milestone payments it will receive from now until product launch in FSGS?**

20TH BIOSHARES
BIOTECH SUMMIT
21 YEARS OF INNOVATION
2005-2026

DIMERIX
IN CONTEXT

Phase 3 Global Opportunity

5 commercial partners
DMX-200 licensed USA, EU, Canada, Australia, NZ, Japan, China, S.Korea, SEA and GCC[1]

up to $1.9 billion in total development and sales milestone payments **plus** royalties on net sales[1]

Phase 3 trial recruitment complete in trial of DMX-200 in focal segmental glomerulosclerosis (FSGS)[2]

FSGS indication is a **rare disease** that causes scarring of the kidney, leading to irreversible damage[3]

Reduced risk
- Proteinuria endpoint **passed blinded interim** (futility) assessment[1]
- Blinded review confirmed ACTION3 **statistically powered (>90%)** to demonstrate statistical significance of predicted proteinuria treatment effect of DMX-200[4]

Orphan drug designations regulatory, marketing exclusivity and pricing **benefits** in key territories[5]

~$1.9 billion*

5 commercial licensing partners

*total upfront and potential milestone payments + royalties on net sales

Dimerix

1. Based on ASX releases 05 October 2023, 27 May 2024, 07 January 2025, 01 May 2025 and 16 June 2026; SEA = Southeast Asia, GCC = Gulf Cooperation Council; 2. AS release 10 March 2026; 3. ASX release 28 April 2026; 3. Guruswamy Sangameswaran KD, Baradhi KM. Focal Segmental Glomerulosclerosis (July 2021), online: https://www.ncbi.nlm.nih.gov/books/NBK532272/; 4. ASX release 11 March 2024 and 28 April 2026; 5. ASX releases: 14 December 2015, 21 November 2018, 07 June 2021 and 30 September 2025

DMX-652: Phase 2 in acute kidney injury

A complementary, clinical-stage pipeline addition

Large value potential

- Secured a Phase 2 ready asset, which is already FDA cleared & manufactured
- Substantial work to date undertaken by originator means significant early risk already removed[1]

First and best in class

- First-in-class USP30 target that promotes renewal of mitochondria
- DMX-652 targets one of the emerging key drivers of kidney injury and reduces both cellular energy failure and inflammation

Leverages existing expertise

- Dimerix team are experts in kidney disease; capable of identifying high value assets
- Experienced in-house team with proven track record of advancing high value assets through clinical development and into commercialisation

Large and growing market

- No approved therapy for high-risk acute kidney injury patients and growing demand for new therapies[2]
- US$3.5 Billion in 2026
- est. US$7.5 Billion by 2036

Strategic value

- Dimerix has significant optionality over the development and commercialisation direction of DMX-652, as the outright asset owner
- DMX-652 has the potential to be used for a variety of other indications, many of which may also have large markets and unmet medical needs

1. Dimerix internal analysis; Mission Therapeutics MTX-652 development file; 2. Zarbock et al, Intensive Care Med 2023; Vervoort et al, Ann Thorac Surg 2023; 3. Dimerix internal market analysis consensus figure based on meta-analysis of 21 market reports (2026) ; Includes China and Japan markets, label expansion into sepsis-associated AKI (SA-AKI) and contrast-associated AKI

20TH BIOSHARES
BIOTECH SUMMIT
21 YEARS OF INNOVATION
2005-2026

DIVERSIFICATION
BY GEOGRAPHY

Beyond US & EU: growth, diversification, resilience

Most biotech and pharma companies focus on the US and EU because these markets typically provide:

- the highest revenue potential
- strongest pricing power
- established regulatory pathways, and
- greatest influence on global product value

However,

- **China** has become the fastest-growing major market over the past decade,[1] fueled by:
  - an aging population;
  - expanded healthcare coverage; and
  - increasing demand for innovative medicines
- **Japan** has the highest per capita medicine use of the developed markets[1]

Dimerix

1. *The Global Use of Medicines 2025: Outlook to 2029 (2025), IQVIA Institute for Human Data Science www.iqvia.com/-/media/iqvia/pdfs/events/presentation_global-meds-webinar_public.pdf*

Strategic rationale for multi-region development

A multi-region development and partnering strategy is not only about expanding commercial opportunity, but is also a deliberate risk-management approach:

- **Expanding Patient Access:** reaching more patients in need of treatment options
- **Revenue diversification:** reduces dependence on individual region pricing reimbursement environments
- **Economic resilience:** offsets impacts of economic and regulatory uncertainty, budget cuts, or policy changes
- **Faster clinical development:** broader patient access accelerates recruitment and time-to-market
- **Global market access:** enables earlier entry into high-growth markets such as China, Japan, Middle East, and APAC
- **Investor confidence:** creates a more resilient asset with multiple growth pathways and lower concentration risk
- **Strategic flexibility:** allows prioritisation of partnerships and launches based on regional market conditions

ACTION3 adult patient recruitment by territory

FSGS CLINICAL STUDY

Trial designed for potential approval globally



Recruitment completed

(adult population)[1]

333

Adult patients recruited, randomised and dosed (target ≥286)[2]

1. ASX release 15 December 2025; 2. Final numbers of adult patients, ASX release 10 March 2026; paediatric patients will continue to recruit, and will not impact final analysis timelines

Dimerix

Summary of licensing deals for DMX-200 to date

Dimerix has successfully partnered DMX-200 across multiple key markets

Licensing deals collectively valued up to

~AU$1.9 billion

in total upfront and potential milestone fees plus royalties[1-5]

>AU$80 million

in total upfront payments[1-5]

	1 BIOMARIN	2 EVEREST MEDICINES	3 ADVANZ PHARMA	4 FUSO	5 taiba
	United States	China,S.Korea.SEA	EU, CA, AU, NZ	Japan	GCC, Iraq
Upfront	AU$48 million[1]	AU$14.1 million[2]	AU$10.8 milllion[3]	AU$7.2 million[4]	AU$0.5 million[5]
	Upfront	Upfront	Upfront	Upfront + 1st milestone	Upfront
Milestones	Up to AU$892 million[1]	Up to AU$467 million[2]	Up to AU$219 million[3]	Up to AU$100 million[4]	Up to AU$120 million[5]
	Milestones	Milestones	Milestones	Milestones	Milestones
Royalties	Escalating low-teen-low twenties%	Between 10-15%	Escalating mid-teen-20%	Between 15-20%	Starting at 30%
	Royalties	Royalties	Royalties	Royalties	Royalties

Dimerix

1. Based on US conversions & further terms outlined in ASX Announcement on 01 May 2025; 2. Based on US conversions & further terms outlined in ASX Announcement on 16 June 2026; ; 3. Based on Euro conversions & further terms outlined in ASX Announcement on 5 October 2023; 4. Based on Japanese ¥ Yen conversions & further terms outlined in ASX Announcement on 7 January 2025 ; 5. Based on US dollar conversions & further terms outlined in ASX Announcement on 27 May 2024

Geographic diversification of fee revenue

Collectively, five commercial agreements valued up to **A$1.9 billion** across upfront + milestone fees:[1]

On signing		Short Term Potential		Longer Term Potential				
Upfront fees		Milestone Payments		Milestone Payments		Royalties		
A$81 million	+	**A$237 million**	+	**A$1.56 billion**		**10 – 30 %**	=	Diversified revenue & risk sharing with licensing partners
In licensing fees		Between now and commercial launch		Post commercial launch		Post commercial launch		

*Upfront and development milestones collectively **A$318 million***

Dimerix

Based on ASX releases 05 October 2023, 27 May 2024, 07 January 2025, 01 May 2025 and 16 June 2026

20TH BIOSHARES
BIOTECH SUMMIT
21 YEARS OF INNOVATION
2005-2026

DIVERSIFICATION
BY ASSET

Diversifying by asset: introducing DMX-652

A first-in-class, oral, once-daily USP30 inhibitor for the prevention of acute kidney injury in high-risk patients undergoing cardiac surgery

Small molecule

New chemical entity; oral capsule formulation; GMP-grade API available to support Phase 2 clinical trial

Once-daily dosing

Convenient dosing schedule to provide pre-operative and post operative USP30 inhibition

Well tolerated

Phase 1 multi-part study completed in 109 healthy volunteers, (85 volunteers administered DMX-652) no serious adverse events and wide therapeutic margin

Phase 2 ready

IND open, approved protocol and established global medical advisory board

Key value proposition with encouraging safety profile

What is AKI associated with cardiac surgery

Currently no approved disease-modifying therapies

1 Cardiac Surgery



Cardiopulmonary bypass starves the kidney of oxygen (ischaemia) and causes oxidative stress in kidney cells

2 Ischaemia



Healthy mitochondria

Kidney starved of oxygen

Damaged mitochondria causes rupture of the mitochondrial membrane



~26%

of patients undergoing cardiac surgery suffer kidney injury

increases to

30-50%

in high-risk patients

3 Reperfusion: restores blood flow to kidney

Mitochondria rupture



kidney damage caused by a massive influx of reactive oxygen species (ROS) that leads to cell death

AKI



Sudden decline in kidney function (hours)

Drives ICU stays, dialysis, mortality and/or progression to Chronic Kidney Disease

Mitochondria = "batteries" for the kidney cell
The kidney has the second-highest mitochondrial content and oxygen consumption in the body to fuel intense energy demands

Source: Scurt FG et al, Kidney360 2024; Zarbock A et al, Intensive Care Med 2023; KDIGO clinical practice guidelines for AKI

Proposed phase 2 clinical trial design

A multicentre, double-blind, randomised, placebo-controlled study evaluating the safety and efficacy of DMX-652 in patients at high risk of AKI following cardiac surgery (n=160)



Primary endpoint

AKI incidence by 7 days post-surgery

Secondary endpoints

Safety and tolerability — PK — MAKE30 — MAKE90

Source: Mission Therapeutics MTX-652 Phase 2 protocol (FDA Study-May-Proceed, 2023); Dimerix MTX-652 development plan (2026); MAKE 30 & MAKE 90 = Major Adverse Kidney Events occurring at 30 or 90 days

Dimerix

DMX-200 and DMX-652: complementary growth pillars

Strategic fit: shared renal capabilities, shared regulatory/clinical infrastructure, shared small-molecule know-how

DMX-200		DMX-652
Focal Segmental Glomerulosclerosis (FSGS) rare **kidney** disease	1 **Shared kidney disease focus**	1 Acute **kidney** injury associated with cardiac surgery
CCR2 inhibitor that modulates inflammatory pathways involved in kidney damage	2 **Different Mechanisms of Action**	2 **USP30 inhibitor** designed to enhance mitophagy and mitochondrial quality control in damaged cells
existing in-house infrastructure and global network	3 **Shared Development Infrastructure**	3 Can **leverage existing** expertise in clinical, regulatory, manufacturing, nephrology networks, know-how, and commercial relationships
more advanced, **near-commercialisation** asset with Phase 3 fully recruited and commercial partnering activity	4 **Balanced Risk and Timing**	4 provides a **new growth engine**, with an open IND, FDA clearance to proceed to Phase 2, and completed Phase 1 safety studies

1. ASX release 10 March 2026; 2. ASX releases March 2024 and April 2026; 3. ASX releases 05 October 2023, 27 May 2024, 07 January 2025; 01 May 2025 and 16 June 2026; 4. ASX release 17 July 2026

Key potential value inflection points

Disciplined, stage-gated capital deployment focused on the clinical value inflection points[1]



Two clinically differentiated assets in renal disease, addressing two separate high unmet need indications with independent timelines; building a steady cadence of value-creating milestones

1. Based on current anticipated activities timeline

Corporate overview

Ticker Symbol	ASX: DXB
Cash Balance (Jun26)*	$16.2 million
Market Capitalisation[1]	$174 million
Share price[1]	$0.29
Total ordinary shares on issue[1]	600,396,776
Average Daily Liquidity by value for past 90 trading days[2]	$0.85 million

**excluding ~$24 million to be received from :*

- *~AU$14 million Everest upfront payment [3]*
- *$10 million loan facility [4]*

SHARE PRICE

SUBSTANTIAL SHAREHOLDERS[3]

Position	Holder Name	Holding	% IC
1	Mr P Meurs	91,090,374	15.3%
TOTAL (TOP 5) Shareholders		**150,392,268**	**25.1%**

1. As at 5 August 2026; 2. Past 90 trading days liquidity as at 5 August 2026; 3. Shareholder register as at 5 August 2026; 3. ASX release 16 June 2026; 4. ASX release 17 July 2026

Dimerix

(ASX:DXB)

A biopharmaceutical company developing innovative new therapies in areas with unmet medical needs, with a core focus on kidney diseases.

SCAN ME

WELL POSITIONED **TO DELIVER** AGAINST STRATEGIC PLAN

ESG Statement

Dimerix is committed to integrating Environmental, Social and Governance (ESG) considerations across the development cycle of its programs, processes and decision making. The Dimerix commitment to improve its ESG performance demonstrate a strong, well-informed management attitude and a values led culture that is both alert and responsive to the challenges and opportunities of doing business responsibly and sustainably.

Dimerix HQ
425 Smith St, Fitzroy 3065
Victoria, Australia
T. +61 1300 813 321
E. investor@dimerix.com